iRadimed (NASDAQ:IRMD) Releases Earnings Results, Beats Estimates By $0.02 EPS

Posted by on Aug 1st, 2026

iRadimed (NASDAQ:IRMD – Get Free Report) posted its quarterly earnings results on Friday. The medical equipment provider reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02, FiscalAI reports. The business had revenue of $20.47 million for the quarter, compared to the consensus estimate of $20.35 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed updated its FY 2026 guidance to 2.090-2.240 EPS and its Q3 2026 guidance to 0.540-0.590 EPS.

Here are the key takeaways from iRadimed’s conference call:

  • Strong customer demand for the new 3870 pump drove bookings to more than double units shipped, with roughly 70% of replacement orders using four-channel quad systems and ASPs exceeding $110,000.
  • IRadimed achieved its target of producing more than 130 3870 pumps in Q2 and plans to exceed 300 units in Q3, with startup costs expected to decline by more than 50% as manufacturing efficiencies improve.
  • Q2 revenue was essentially flat year over year at $20.5 million, while gross margin fell to 74% from 78% and GAAP EPS declined to $0.41 from $0.45 due to the initial 3870 production ramp.
  • Recurring revenue trends remained healthy, including 14% growth in disposables, while domestic patient-monitor sales reached a record 71 units and the company cited strong backlogs across pumps, monitors, and ferromagnetic detection systems.
  • Management reaffirmed full-year 2026 guidance of $91 million–$96 million in revenue and $1.90–$2.05 in GAAP EPS, expects improving margins through the second half, and said a $100 million revenue run rate in Q4 is within reach.

iRadimed Stock Performance

Shares of iRadimed stock traded down $4.35 during midday trading on Friday, reaching $90.86. 308,080 shares of the company’s stock traded hands, compared to its average volume of 111,471. iRadimed has a 52 week low of $57.83 and a 52 week high of $107.90. The company’s 50 day simple moving average is $94.54 and its 200 day simple moving average is $95.70. The company has a market cap of $1.16 billion, a price-to-earnings ratio of 49.65 and a beta of 0.90.

iRadimed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 28th. Stockholders of record on Friday, August 14th will be issued a dividend of $0.20 per share. The ex-dividend date is Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is currently 43.72%.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $120.00.

Get Our Latest Stock Analysis on IRMD

Insider Transactions at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 2,500 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $90.60, for a total transaction of $226,500.00. Following the transaction, the chief executive officer directly owned 2,162,500 shares of the company’s stock, valued at $195,922,500. This represents a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 21,250 shares of company stock valued at $1,836,403 in the last three months. Corporate insiders own 34.60% of the company’s stock.

Institutional Trading of iRadimed

Institutional investors and hedge funds have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. increased its holdings in shares of iRadimed by 410.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock valued at $24,893,000 after acquiring an additional 205,783 shares during the last quarter. Invesco Ltd. lifted its holdings in iRadimed by 473.9% in the 4th quarter. Invesco Ltd. now owns 35,131 shares of the medical equipment provider’s stock worth $3,418,000 after purchasing an additional 29,010 shares during the last quarter. NewEdge Advisors LLC acquired a new stake in iRadimed in the 4th quarter worth approximately $1,679,000. XTX Topco Ltd bought a new stake in iRadimed during the fourth quarter worth approximately $360,000. Finally, Susquehanna Portfolio Strategies LLC bought a new stake in iRadimed during the fourth quarter worth approximately $326,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

More iRadimed News

Here are the key news stories impacting iRadimed this week:

  • Positive Sentiment: Earnings exceeded expectations. iRadimed reported second-quarter non-GAAP diluted EPS of $0.46, above the $0.42 consensus estimate; GAAP diluted EPS was $0.41. The company also reported a 24.48% return on equity and a 27.36% net margin. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
  • Positive Sentiment: 2026 EPS guidance is above analyst expectations. Full-year EPS guidance of $2.09-$2.24 compares with the $1.96 consensus estimate. Third-quarter EPS guidance of $0.54-$0.59 also exceeds the $0.53 consensus. IRADIMED Corporation Q2 2026 Earnings Call Transcript
  • Positive Sentiment: iRadimed declared a regular quarterly dividend of $0.20 per share, providing a direct shareholder return. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
  • Neutral Sentiment: Revenue guidance is broadly in line with expectations. Third-quarter revenue guidance of $23.0-$24.5 million brackets the $23.7 million consensus, while full-year guidance of $91-$96 million is close to the $91.2 million estimate.
  • Negative Sentiment: Revenue growth was weak. Second-quarter revenue reached $20.5 million, up only $0.1 million, or 0.5%, from the prior-year period. That modest growth may have tempered the positive impact of the EPS beat, particularly with shares trading at a trailing price-to-earnings ratio near 50.

iRadimed Company Profile

(Get Free Report)

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

Featured Stories

Earnings History for iRadimed (NASDAQ:IRMD)

Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.